Prostate cancer: Evidence based clinical practice;Cáncer de próstata: Práctica clínica basada en la evidencia

Actas Urologicas Espanolas

Volumn 33, Issue 4, 2009, Pages 344-350

  Reis, Leonardo Oliveira ^a   Sasse, André Deeke ^a   Matheus, Wagner Eduardo ^a   Denardi, Fernandes ^a   Stopiglia, Rafael Mamprim ^a   Da Silva, Mauricio Moreira ^a   Ferreira, Ubirajara ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Evidence based medicine; Guideline; Prostate cancer

Indexed keywords

EVIDENCE BASED MEDICINE; HUMAN; MALE; PROSTATE TUMOR; REVIEW; RISK ASSESSMENT;

EVIDENCE-BASED MEDICINE; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 68349135754     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-4806(09)74158-0     Document Type: Review

References (52)

1. Sackett DL, Rosenbe DR, WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: What it is and what it isn't. BMJ 1996, 312(7023): 71-72.
2. Petrisor BA, Keating J, Schemitsch E. Grading the evidence: Levels of evidence and grades of recommendation. Injury 2006, 37(4):321-327.
3. Oxford Centre for Evidence-based Medicine Levels of Evidence. In: Centre for Evidence-Based Medicine, 2001. www.cemb.net/index.aspx?o=1025,
4. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998 Sep 16;280(11):969-974.
5. Ilic D, O'Connor D, Green S, Wilt T. Screening for prostate cancer. Cochrane Database Syst Rev. 2006;3:CD004720.
6. Issa MM, Zasada W, Ward K, Hall JA, Petros JA, Ritenour CW, et al. The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States Veterans referred for prostate biopsy. Cancer detection and prevention. 2006;30(3):269-275.
7. Ashley T. Using predictive value, sensitivity and specificity to interpret laboratory tests: PSA for the diagnosis of prostate cancer. Journal of insurance medicine (New York, NY.) 2005;37 (4):261-263.
8. Maattanen L, Hakama M, Tammela TL, Ruutu M, Ala-Opas M, Juusela H, et al. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial. British journal of cancer. 2007 Jan 15;96(1):56-60.
9. Concato J, Wells CK. Prostate-specific antigen Velocity' as a diagnostic test for prostate cancer. J Investig Med. 2006 Nov;54 (7):361-364.
10. Gregorio EP, Grando JP, Saqueti EE, Almeida SH, Moreira HA, Rodrigues MA. Comparison between PSA density, free PSA percentage and PSA density in the transition zone in the detection of prostate cancer in patients with serum PSA between 4 and 10 ng/mL. Int Braz J Urol. 2007 Mar- Apr;33(2): 151-160.
11. Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and metaanalysis. Eur Urol. 2005 Sep;48(3):386-399; discussion 98-99.
12. Sabbagh R, McCormack M, Peloquin F, Faucher R, Perreault JP, Perrotte P, et al. A prospective randomized trial of 1-day versus 3-day antibiotic prophylaxis for transrectal ultrasound guided prostate biopsy. The Canadian journal of urology. 2004 Apr; 11(2):2216-2219.
13. Heijmink SW, van Moerkerk H, Kiemeney LA, Witjes JA, Frauscher F Barentsz JO. A comparison of the diagnostic performance of systematic versus ultrasound-guided biopsies of prostate cancer. European radiology, 2006 Apr; 16(4):927-938.
14. Cevik I, Dillioglugil O, Zisman A, Akdas A. Combined &periprostatic and periapical& local anesthesia is not superior to &periprostatic& anesthesia alone in reducing pain during Tru-Cut prostate biopsy. Urology. 2006 Dec;68(6): 1215-9.
15. Zackrisson B, Aus G, BeDRdahl S, Lilja H, Lodding P, Pihl CG, et al. The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. J Urol. 2004 Apr; 171(4): 1500-1503.
16. Mancuso PA, Chabert C, Chin P, Kovac P, Skyring T, Watt WH, et al. Prostate cancer detection in men with an initial diagnosis of atypical small acinar proliferation. BJU Int. 2007 Jan;99(1): 49-52.
17. Rabets JC, Jones JS, Patel A, Zippe CD. Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol. 2004 Jul;172(1):94-97.
18. Remzi M, Dobrovits M, Reissigl A, Ravery V, Waldert M, Wiunig C, et al. Can Power Doppler enhanced transrectal ultrasound guided biopsy improve prostate cancer detection on first and repeat prostate biopsy? Eur Urol, 2004 Oct;46(4):451-456.
19. Karaman CZ, Unsal A, Akdilli A, Taskin F, Erol H. The value of contrast enhanced power Doppler ultrasonography in differentiating hypoehoic lesions in the peripheral zone of prostate. European journal of radiology, 2005 Apr;54(1): 148-155.
20. Prando A, Kurhanewicz J, BoDRes AP, Oliveira EM, Jr., Figueiredo E, Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience. Radiology. 2005 Sep;236(3):903-910,
21. Lorente JA, Valenzuela H, Moróte J, Gelabert A. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med. 1999 Jun;26(6):625-632.
22. Kosuda S, Yoshimura I, Aizawa T, Koizumi K, Akakura K, Kuyama J, et al, Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multi- center retrospective study in Japan. Cancer. 2002 Feb 15;94(4):964-972,
23. Wymenga LF, Boomsma JH, Groenier K, Piers DA, Mensink HJ. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase. BJU Int. 2001 Aug;88(3):226-230,
24. Coakley FV, Qayyum A, Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol. 2003 Dec; 170(6 Pt 2):S69- 75; discussion S-6,
25. Tempany CM, Zhou X, Zerhouni EA, Rifkin MD, Quint LE, Piccoli CW, et al, Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. Radiology. 1994 Jul;192(1):47-54.
26. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003 Jun 19;348(25):2491-2499,
27. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically oDRan- confined prostate cancer. Urology. 2001 Jan;57(1): 108-111,
28. Klotz L. Active surveillance with selective delayed intervention for favorable risk prostate cancer. Urol Oncol. 2006 Jan-Feb;24(1):46-50,
29. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004 Jul 8;351(2):125-135.
30. Choo R, DeBoer G, Klotz L, Danjoux C, Morton GC, Rakovitch E, et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys. 2001 Jul l;50(3):615-620,
31. Altwein JE. Enhancing the efficacy of radical prostatectomy in locally advanced prostate cancer. Urol Int. 1998;60 Suppl 2:2-10; discussion 35,
32. Hill JR, Fine SW, Zhang J, Eastham JA. Radical prostatectomy for clinical T3 disease: expanding indications while optimizing cancer control and quality of life. Nat Clin Pract Urol. 2007 Aug;4(8):451-454.
33. Salonia A, Suardi N, Crescenti A, Zanni G, Fantini GV, Gallina A, et al, Pfannenstiel versus vertical laparotomy in patients undeDRoing radical retropubic prostatectomy with spinal anesthesia: results of a prospective, randomized trial. Eur Urol. 2005 Feb;47(2):202-208.
34. Malmstrom PU. Lymph node staging in prostatic carcinoma revisited. Acta oncológica (Stockholm, Sweden). 2005;44(6): 593-598,
35. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Jr., Miller DW, Adams JA, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. Jama. 2005 Sep 14;294(10): 1233-1239.
36. Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol. 2004 Mar; 171(3): 1098-1104,
37. Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, NuernbeDR N, et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Mar 15;58 (4): 1048-1055.
38. Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005 Aug 13-19;366(9485): 572-578.
39. Kumar S, Shelley M, Harrison C, Coles B, WiltTJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006(4):CD006019.
40. Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. 2005 Nov;6(11):841-850.
41. Bolla M, van Tienhoven G, de Reijke TM, van den BeDRh AC, van der Meijden AP, Poortmans PM, et al., editors. Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT-Results of the randomized EORTC Phase III trial 22961. 2007 ASCO Annual Meeting; 2007; Chicago - USA
42. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of suDRical outcomes. J Urol. 2007 Feb;177(2):540-545.
43. Sandler HM, EisenbeDRer MA. Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy. J Urol. 2007 Sep;178(3 Pt 2):S20-24.
44. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group, Lancet. 2000 Apr 29;355(9214): 1491-1498.
45. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Annals of internal medicine. 2000 Apr 4; 132(7): 566-577.
46. Miller K, Steiner U, Lingnau A, Keilholz U, Witzsch U, Haider A, et al., editors. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. 2007 ASCO Annual Meeting; 2007; Chicago - USA.
47. Ryan CJ, Small EJ. Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology. 2003 Dec 29;62 Suppl 1:87-94,
48. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 Oct 7;351(15): 1502-1512,
49. Kaasa S, Brenne E, Lund JA, Fayers P, Falkmer U, HolmbeDR M, et al, Prospective randomised multicenter trial on single fraction radiotherapy (8 Gy x 1) versus multiple fractions (3 Gy x 10) in the treatment of painful bone metastases. Radiother Oncol. 2006 Jun;79(3):278-284.
50. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer, Journal of the National Cancer Institute. 2004 Jun 2;96(11):879-882,
51. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, et al, Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004 May;63(5):940- 945.
52. Moróte J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, et al, Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology. 2007 Mar;69(3):500-504,